Table 1.
S.No. | Probiotic strains | Features | Potential effect | References |
---|---|---|---|---|
1 | Akkermansia muciniphila | Strict anaerobe, mucin degrader, can colonize in ileum, cecum and colon | Reduces body fat, serum triglyceride, fasting glucose levels and enhances insulin sensitivity | [104, 105] |
2 | Brevibacillus laterosporus | Spore forming, Antimicrobial peptide producer | Antibacterial and antitumor activity | [106, 107] |
3 | Bacteroides xylanisolvens | Strictly anaerobic, resistant to gastric enzymes and low-pH conditions | Increases the level of TFα-specific immunoglobulin M serum antibodies | [108, 109] |
4 | Bifidobacterium bifidum | Acetate and propionate producer | Greater cytokine (IL-6) production and active phagocytic property | [110, 111] |
5 | Bifidobacterium breve | Acetate producer and resistant to low-pH | Anti-infectious activity | [112] |
6 | Bifidobacterium infantis | Acetate and propionate producer | Therapeutic effect against irritable bowel syndrome and inhibits the secretion of allergen-induced IgE | [113–115] |
7 | Bifidobacterium lactis | Aerotolerant | Plasminogen binding activity and regulates the co-stimulatory molecules (CD80, CD86, CD40), required for an effective activation of T-cells | [116, 117] |
8 | Bifidobacterium longum | Acetate and propionate producer | modulate the immune system through IL-10 production | [118] |
9 | Clostridium butyricum | Butyrate producer | Neuroprotective effects against vascular dementia | [119] |
10 | Faecalibacterium prausnitzii | Strictly anaerobic | anti-inflammatory effects by blocking NF-kappaB activation and IL-8 production | [120, 121] |
11 | Lactobacillus acidophilus | Lactic and acetic acids producer | Reduces the level of cholesterol through reverse transport in macrophages | [122] |
12 | Lactobacillus brevis | γ-Aminobutyric acid (GABA) producer |
Antidepressant, antihypertensive, and anti-diabetic effects |
[123] |
13 | Lactobacillus bulgaricus | Lactic acid producer | Anti-microbial peptide production | [124] |
14 | Lactobacillus casei group (LCG) | Low-pH tolerant and amino acid utilization | Anti-inflammatory response | [125, 126] |
15 | Lactobacillus gasseri | Bile tolerant, cholesterol binding ability | Reduces body weight and adipose tissue mass | [127, 128] |
16 | Lactobacillus helveticus | Lactic acid producer with high protease activity | Inhibits the proliferation of lymphocytes through a suppression of JNK signaling pathway | [129] |
17 | Lactobacillus plantarum | Anti-microbial peptides producer | Cholesterol lowering activity | [130, 131] |
18 | Lactobacillus salivarius | Bile and pH tolerant | Reduces pathogenicity of C. albicans by inhibiting the biofilm formation | [132, 133] |
19 | Lactococcus lactis | Bacteriocins and lactic acid producer | Used as a vehicle to deliver therapeutics such as cytokines into the human body | [134] |
20 | Pediococcus acidilactici | Bacteriocins and lactic acid producer | Antimicrobial activity against several gram-positive and gram-negative food-spoilage and food-borne pathogens | [135] |
21 | Streptococcus thermophiles | Lactic acid producer | Suppresses the Th17 response in inflamed intestines, useful in inflammatory bowel disease | [136] |
22 | Enterococcus faecium | Bacteriocin producer | Modulate the Th2-mediated pathologic response | [137, 138] |
23 | Saccharomyces boulardii (Yeast) | Resistant to gastric enzymes | Beneficial in Clostridium difficile-associated disease, antibiotic-associated diarrheas, and acute infectious diarrheas | [139, 140] |